{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:47:54Z","timestamp":1784288874045,"version":"3.55.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK117004"],"award-info":[{"award-number":["DK117004"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK106491"],"award-info":[{"award-number":["DK106491"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK48522"],"award-info":[{"award-number":["DK48522"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0236353","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T22:42:03Z","timestamp":1596148923000},"page":"e0236353","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4229-4858","authenticated-orcid":true,"given":"Michael","family":"Kriss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2087-4405","authenticated-orcid":true,"given":"Lucy","family":"Golden-Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faridoddin","family":"Mirshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Wendy","family":"Setiawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo R.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"issue":"11","key":"pone.0236353.ref001","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","article-title":"From NAFLD to NASH to cirrhosis-new insights into disease mechanisms","volume":"10","author":"A Wree","year":"2013","journal-title":"Nature reviews Gastroenterology & hepatology"},{"issue":"6","key":"pone.0236353.ref002","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/MOL.0b013e32834c7cfc","article-title":"Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic","volume":"22","author":"JM Schattenberg","year":"2011","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"pone.0236353.ref003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"ZM Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"pone.0236353.ref004","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jhep.2016.07.033","article-title":"NAFLD and liver transplantation: Current burden and expected challenges","volume":"65","author":"R Pais","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0236353.ref005","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/hep.22734","article-title":"Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis","volume":"49","author":"V Paradis","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"pone.0236353.ref006","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/hep.29724","article-title":"Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"68","author":"ZM Younossi","year":"2018","journal-title":"Hepatology"},{"key":"pone.0236353.ref007","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease","volume":"13","author":"JP Arab","year":"2018","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"pone.0236353.ref008","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"D Schuppan","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"pone.0236353.ref009","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"N Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"pone.0236353.ref010","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O","year":"2016","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0236353.ref011","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"DE Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"pone.0236353.ref012","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbadis.2015.10.028","article-title":"Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis","volume":"1862","author":"JD Coombes","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"pone.0236353.ref013","doi-asserted-by":"crossref","first-page":"e0175336","DOI":"10.1371\/journal.pone.0175336","article-title":"Impact of human monocyte and macrophage polarization on NLR expression and NLRP3 inflammasome activation","volume":"12","author":"F Awad","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"pone.0236353.ref014","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2016.01.025","article-title":"Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe?","volume":"150","author":"B Gao","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"pone.0236353.ref015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/hep4.1160","article-title":"Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis","volume":"2","author":"AJ Kruger","year":"2018","journal-title":"Hepatol Commun"},{"issue":"5","key":"pone.0236353.ref016","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"SL Friedman","year":"2018","journal-title":"Hepatology"},{"issue":"3\u20134","key":"pone.0236353.ref017","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12079-009-0068-0","article-title":"The role of osteopontin in inflammatory processes","volume":"3","author":"SA Lund","year":"2009","journal-title":"J Cell Commun Signal"},{"issue":"7","key":"pone.0236353.ref018","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1136\/gutjnl-2013-306484","article-title":"Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice","volume":"64","author":"JD Coombes","year":"2015","journal-title":"Gut"},{"issue":"1","key":"pone.0236353.ref019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010007","article-title":"Is Osteopontin a Friend or Foe of Cell Apoptosis in Inflammatory Gastrointestinal and Liver Diseases?","volume":"19","author":"T Iida","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"11","key":"pone.0236353.ref020","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep4.1237","article-title":"Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease","volume":"2","author":"O Glass","year":"2018","journal-title":"Hepatol Commun"},{"key":"pone.0236353.ref021","article-title":"Neutralizing antibody against osteopontin attenuates non-alcoholic steatohepatitis in mice","author":"M Honda","year":"2020","journal-title":"J Cell Commun Signal"},{"issue":"1","key":"pone.0236353.ref022","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.dld.2012.08.017","article-title":"Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease","volume":"45","author":"Y Yilmaz","year":"2013","journal-title":"Dig Liver Dis"},{"key":"pone.0236353.ref023","article-title":"Dietary Lipids Differentially Shape NASH Progression and the Transcriptome of Kupffer Cells and Infiltrating Macrophages","author":"B McGettigan","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"pone.0236353.ref024","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12967-018-1490-y","article-title":"CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading","volume":"16","author":"X Chu","year":"2018","journal-title":"J Transl Med"},{"issue":"3","key":"pone.0236353.ref025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/hep.28252","article-title":"Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes","volume":"63","author":"SH Ibrahim","year":"2016","journal-title":"Hepatology"},{"key":"pone.0236353.ref026","doi-asserted-by":"crossref","first-page":"28786","DOI":"10.1038\/srep28786","article-title":"CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis","volume":"6","author":"K Tomita","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0236353.ref027","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12876-020-1165-z","article-title":"Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis","volume":"20","author":"X Ma","year":"2020","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"pone.0236353.ref028","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"33","author":"S Verma","year":"2013","journal-title":"Liver Int"},{"issue":"5","key":"pone.0236353.ref029","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"S McPherson","year":"2015","journal-title":"J Hepatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0236353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T06:46:48Z","timestamp":1667630808000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0236353"}},"subtitle":[],"editor":[{"given":"Pavel","family":"Strnad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0236353","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,30]]}}}